Brater DC - Search Results

1

Controversies in COX-2 selective inhibition.

Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, Breedveld FC, Brune K, Burmester GR, Crofford LJ, Dougados M, DuBois RN, Fitzgerald GA, Frishman W, García Rodríguez LA, Hochberg MC, Kalden JR, Laine L, Langman MJ, Prescott SM, van de Putte LB, Whelton A, White WB, Willaims GH. Simon LS, et al. Among authors: brater dc. J Rheumatol. 2002 Jul;29(7):1501-10. J Rheumatol. 2002. PMID: 12136912 Review. No abstract available.

2

Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.

Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Krum H, et al. Among authors: brater dc. J Hypertens. 2009 Apr;27(4):886-93. doi: 10.1097/HJH.0b013e328325d831. J Hypertens. 2009. PMID: 19516186 Clinical Trial.

3

Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.

Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Krum H, et al. Among authors: brater dc. Eur J Heart Fail. 2009 Jun;11(6):542-50. doi: 10.1093/eurjhf/hfp054. Epub 2009 Apr 19. Eur J Heart Fail. 2009. PMID: 19380329 Free article. Clinical Trial.

4

Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.

Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CP. Krum H, et al. Among authors: brater dc. Cardiovasc Ther. 2012 Dec;30(6):342-50. doi: 10.1111/j.1755-5922.2011.00283.x. Epub 2011 May 25. Cardiovasc Ther. 2012. PMID: 21884017 Free article. Clinical Trial.

5

Renal effects of COX-2-selective inhibitors.

Brater DC, Harris C, Redfern JS, Gertz BJ. Brater DC, et al. Am J Nephrol. 2001 Jan-Feb;21(1):1-15. doi: 10.1159/000046212. Am J Nephrol. 2001. PMID: 11275626 Review.

6

Risk of hyperkalemia associated with selective COX-2 inhibitors.

Aljadhey H, Tu W, Hansen RA, Blalock S, Brater DC, Murray MD. Aljadhey H, et al. Among authors: brater dc. Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1194-8. doi: 10.1002/pds.2011. Pharmacoepidemiol Drug Saf. 2010. PMID: 20842761 Free PMC article.

7

Evaluation of etodolac in subjects with renal impairment.

Brater DC. Brater DC. Eur J Rheumatol Inflamm. 1990;10(1):44-55. Eur J Rheumatol Inflamm. 1990. PMID: 2146131

8

Renal effects of cyclooxygenase-2 selective inhibitors.

Harris CJ, Brater DC. Harris CJ, et al. Among authors: brater dc. Curr Opin Nephrol Hypertens. 2001 Sep;10(5):603-10. doi: 10.1097/00041552-200109000-00009. Curr Opin Nephrol Hypertens. 2001. PMID: 11496053 Review.

9

Profile of etodolac: pharmacokinetic evaluation in special populations.

Brater DC, Lasseter KC. Brater DC, et al. Clin Rheumatol. 1989 Mar;8 Suppl 1:25-35. doi: 10.1007/BF02214107. Clin Rheumatol. 1989. PMID: 2525981 Review.

10

Renal effects of cyclooxygyenase-2-selective inhibitors.

Brater DC. Brater DC. J Pain Symptom Manage. 2002 Apr;23(4 Suppl):S15-20; discussion S21-3. doi: 10.1016/s0885-3924(02)00370-6. J Pain Symptom Manage. 2002. PMID: 11992745 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

210 results

Search Page